IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: David Jackson et al.

U.S. APPLICATION NO.: 10/525,301

35 U.S.C. §371 FILING DATE: August 29, 2005

INTERNATIONAL APPLICATION NO.: PCT/AU2003/001018

INTERNATIONAL FILING DATE: August 12, 2003

TITLE: Novel Immunogenic Lipopeptides Comprising

T-helper and B-cell Epitopes

EXAMINER: David Lukton

GROUP ART UNIT: 1654

ATTY. DKT. NO.: 23133-09966US

CERTIFICATE OF ELECTRONIC (EFS-WEB) TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with 37 C.F.R. § 1.8(a)(i)(C) from the Pacific Time Zone of the United States on the local date shown below.

Dated: January 24, 2008 By: /Susan T. Hubl/

Susan T. Hubl, Reg. No.: 47,668

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred.

- Copies of any foreign patent documents and non-patent literature cited herein are enclosed.
- Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted, David Jackson et al.

Dated: January 24, 2008 By: /Susan T. Hubl/

Susan T. Hubl, Ph.D., Patent Agent

Reg. No.: 47,668 Fenwick & West LLP Silicon Valley Center 801 California Street

Mountain View, CA 94041

Tel.: (415) 875-2316 Fax.: (650) 938-5200